Heat Biologics

172 articles with Heat Biologics

• Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results

  1/27/2021

  Heat Biologics, Inc.announces the publication of additional preclinical COVID-19 results in Frontiers in Immunology, a leading peer reviewed journal, which is available online.

• Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021

  1/20/2021

  Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference.

• Heat Biologics Commences Manufacturing Process for ZVX-60

  1/19/2021

  Heat Biologics, Inc. announces it has transferred its gp96-based COVID-19 vaccine cell line to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19.

• Heat Biologics Promotes William L. Ostrander to Chief Financial Officer

  1/11/2021

  Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021.

• Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

  1/8/2021

  Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

• Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19

  12/16/2020

  Heat Biologics, Inc. (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has completed its gp96-based COVID-19 vaccine cell line which is being developed for use as either a standalone vaccine or in combination with other vaccines

• Heat Biologics Provides Business Update

  12/10/2020

  Heat Biologics, Inc. today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-7. The reverse stock split will take effect as of 12:01 a.m. ET, December 11, 2020.

• 

  Biotechs Developing Innovative Ways to Activate the Immune System Against COVID-19

  12/8/2020

  BioSpace spoke with a few companies that have some ingenious ideas at different stages of preclinical and clinical development.

• Heat Biologics Provides Third Quarter 2020 Business Update

  11/9/2020

  Heat Biologics, Inc. (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the third quarter

• Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator

  10/7/2020

  Heat Biologics, Inc. announced it has been issued a new US patent covering compositions of matter that are part of Heat's gp96 platform in combination with Inducible T cell Co-stimulator ligand or ICOSL, a T cell immune booster, in a single therapy.

• Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

  9/9/2020

  Heat Biologics, Inc. today announced that Jeff Wolf, CEO of Heat Biologics, will participate on a virtual panel, entitled, New Approaches to COVID-19:

• Heat Biologics Issued Key Patent on Combination Platform Therapy

  9/2/2020

  Heat Biologics, Inc. today announced it has been issued a patent (US Patent No. 10,758,611)

• Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results

  8/26/2020

  Data supports a differentiated gp96-based COVID-19 vaccine that induces systemic and tissue-specific (lung) memory CD8+ T cells Gp96-based vaccine generates tissue-resident memory CD8+ T cells that may be instrumental in eradicating SARS-CoV-2 infected cells Tissue specific memory CD8+ T cells potentially important for compromised patient populations

• Heat Biologic's COVID-19 Vaccine Demonstrates Robust T Cell Driven Immune Response to SARS-CoV-2 in Preclinical Studies

  8/13/2020

  Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, reported preclinical data for Heat's gp96-based COVID-19.

• Heat Biologics Provides Second Quarter 2020 Business Update

  8/7/2020

  Heat Biologics, Inc.today provided financial, clinical and operational updates for the second quarter ended June 30, 2020.

• Heat Biologics Highlights Importance of T cell Immunity to Prevent COVID-19

  8/5/2020

  White paper highlights potential of Heat's vaccine to boost T cell immunity, alone or in combination with other vaccines

• Heat Biologics COVID-19 Vaccine Demonstrates Immunogenicity Proof-of-Concept in Pre-Clinical Studies

  7/29/2020

  Confirms stimulation of human-HLA-restricted transgenic mouse T-cells against immunodominant epitopes of SARS-CoV-2 Spike protein

• Heat Biologics Regains Compliance with Nasdaq Minimum Bid Price Rule

  7/27/2020

  DURHAM, NC / ACCESSWIRE / July 27, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine product candidate, today announced that on July 24, 2020, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, Inc. ("Nasdaq"), confirming that

• Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35

  6/22/2020

  Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that the first patient has been treated in the Company's first-in-human Phase 1 clinical trial evaluating PTX-35,

• Heat Biologics Provides Update on COVID-19 Vaccine Efforts

  6/5/2020

  Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including a novel COVID-19 vaccine and multiple oncology product candidates, announced further progress on its COVID-19 vaccine program.